Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) reported first-quarter financial results for 2020, highlighting a revenue increase to $5.7 million from $3.7 million in Q1 2019, largely due to higher grant revenue.
However, the company experienced a net loss of $77.2 million or $0.71 per share, significantly up from a $28.7 million loss last year. R&D expenses surged to $65.0 million driven by collaborations and clinical trial costs. The company is actively advancing its COVID-19 programs with ongoing clinical trials and partnerships with major firms like GSK and Samsung Biologics.
Vir Biotechnology, Inc. has announced that its 2020 Annual Meeting of Stockholders, originally scheduled for May 20, 2020, will now be conducted in a virtual-only format due to COVID-19 concerns. The online meeting will commence at 10:00 a.m. Pacific Time, with access beginning at 9:45 a.m. Stockholders of record as of March 27, 2020, can attend using a 16-digit control number. Guests can listen in but cannot vote or ask questions. The company encourages stockholders to vote in advance, regardless of attendance.
Vir Biotechnology (Nasdaq: VIR) has announced that its CEO, George Scangos, Ph.D., will present virtually at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 12:40 pm PT / 3:40 pm ET. Investors and interested parties can access the live webcast through the Vir website, where it will also be archived for 30 days afterward. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies and has initiatives targeting various viruses, including SARS-CoV-2 and hepatitis B.